Advanced search
1 file | 1.34 MB

A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing

(2018) HAEMATOLOGICA. 103(12). p.E585-E589
Author
Organization
Abstract
Graft-versus-host disease (GvHD) assessment has been shown to be a challenge for healthcare professionals, leading to the development of the eGVHD App (www.uzleuven.be/egvhd). In this study, we formally evaluated the accuracy of using the App compared to traditional assessment methods to assess GvHD. Our national multicenter randomized controlled trial involved seven Belgian transplantation centers and 78 healthcare professionals selected using a 2-stage convenience sampling approach between January and April 2017. Using a 1:1 randomization stratified by profession, healthcare professionals were assigned to use either the App ("APP") or their usual GvHD assessment aids ("No APP") to assess the diagnosis and severity score of 10 expert-validated clinical vignettes. Our main outcome measure was the difference in accuracy for GvHD severity scoring between both groups. The odds of being correct were 6.14 (95% CI: 2.83-13.34) and 6.29 (95% CI: 4.32-9.15) times higher in favor of the "APP" group for diagnosis and scoring, respectively (P<0.001). Appassisted GvHD severity scoring was significantly superior for both acute and chronic GvHD, with an Odds Ratio of 17.89 and 4.34 respectively (P<0.001) and showed a significantly increased inter-observer agreement compared to standard practice. Despite a mean increase of 24 minutes (95% CI: 20.45-26.97) in the time needed to score the whole GvHD test package in the "APP" group (P<0.001), usability feedback was positive. The eGVHD App shows superior GvHD assessment accuracy compared to standard practice and has the potential to improve the quality of outcome data registration in allogeneic stem cell transplantation.
Keywords
CONSENSUS DEVELOPMENT PROJECT, WORKING GROUP-REPORT, CLINICAL-TRIALS, THERAPEUTIC RESPONSE, NIH CRITERIA, ACUTE GVHD, DIAGNOSIS, MARROW, CGVHD

Downloads

  • verboom haematologica.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.34 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Verboom, Karen, Wouter Van Loocke, Pieter-Jan Volders, Bieke Decaesteker, Francisco Avila Cobos, Simon Bornschein, Charles E de Bock, et al. 2018. “A Comprehensive Inventory of TLX1 Controlled Long Non-coding RNAs in T-cell Acute Lymphoblastic Leukemia Through polyA+ and Total RNA Sequencing.” Haematologica 103 (12): E585–E589.
APA
Verboom, K., Van Loocke, W., Volders, P.-J., Decaesteker, B., Avila Cobos, F., Bornschein, S., de Bock, C. E., et al. (2018). A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing. HAEMATOLOGICA, 103(12), E585–E589.
Vancouver
1.
Verboom K, Van Loocke W, Volders P-J, Decaesteker B, Avila Cobos F, Bornschein S, et al. A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing. HAEMATOLOGICA. 2018;103(12):E585–E589.
MLA
Verboom, Karen et al. “A Comprehensive Inventory of TLX1 Controlled Long Non-coding RNAs in T-cell Acute Lymphoblastic Leukemia Through polyA+ and Total RNA Sequencing.” HAEMATOLOGICA 103.12 (2018): E585–E589. Print.
@article{8577460,
  abstract     = {Graft-versus-host disease (GvHD) assessment has been shown to be a challenge for healthcare professionals, leading to the development of the eGVHD App (www.uzleuven.be/egvhd). In this study, we formally evaluated the accuracy of using the App compared to traditional assessment methods to assess GvHD. Our national multicenter randomized controlled trial involved seven Belgian transplantation centers and 78 healthcare professionals selected using a 2-stage convenience sampling approach between January and April 2017. Using a 1:1 randomization stratified by profession, healthcare professionals were assigned to use either the App ({\textacutedbl}APP{\textacutedbl}) or their usual GvHD assessment aids ({\textacutedbl}No APP{\textacutedbl}) to assess the diagnosis and severity score of 10 expert-validated clinical vignettes. Our main outcome measure was the difference in accuracy for GvHD severity scoring between both groups. The odds of being correct were 6.14 (95\% CI: 2.83-13.34) and 6.29 (95\% CI: 4.32-9.15) times higher in favor of the {\textacutedbl}APP{\textacutedbl} group for diagnosis and scoring, respectively (P{\textlangle}0.001). Appassisted GvHD severity scoring was significantly superior for both acute and chronic GvHD, with an Odds Ratio of 17.89 and 4.34 respectively (P{\textlangle}0.001) and showed a significantly increased inter-observer agreement compared to standard practice. Despite a mean increase of 24 minutes (95\% CI: 20.45-26.97) in the time needed to score the whole GvHD test package in the {\textacutedbl}APP{\textacutedbl} group (P{\textlangle}0.001), usability feedback was positive. The eGVHD App shows superior GvHD assessment accuracy compared to standard practice and has the potential to improve the quality of outcome data registration in allogeneic stem cell transplantation.},
  author       = {Verboom, Karen and Van Loocke, Wouter and Volders, Pieter-Jan and Decaesteker, Bieke and Avila Cobos, Francisco and Bornschein, Simon and de Bock, Charles E and Kalender Atak, Zeynep and Clappier, Emmanuelle and Aerts, Stein and Cools, Jan and Soulier, Jean and Taghon, Tom and Van Vlierberghe, Pieter and Vandesompele, Jo and Speleman, Franki and Durinck, Kaat},
  issn         = {0390-6078},
  journal      = {HAEMATOLOGICA},
  language     = {eng},
  number       = {12},
  pages        = {E585--E589},
  title        = {A comprehensive inventory of TLX1 controlled long non-coding RNAs in T-cell acute lymphoblastic leukemia through polyA+ and total RNA sequencing},
  url          = {http://dx.doi.org/10.3324/haematol.2018.190587},
  volume       = {103},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: